Optical information reproduction apparatus and optical information reproduction method
    1.
    发明授权
    Optical information reproduction apparatus and optical information reproduction method 有权
    光信息再现装置和光信息再现方法

    公开(公告)号:US08520484B2

    公开(公告)日:2013-08-27

    申请号:US13088462

    申请日:2011-04-18

    IPC分类号: G11B7/00

    CPC分类号: G11B7/0065 G11B7/08564

    摘要: In an optical information reproduction method for reproducing information using holography from a medium which records an interference pattern generated when overlapping a signal beam and a reference beam, the reference beam is radiated to the medium at a reference beam angle with a predetermined range for reproducing the information, a reproduction beam is generated by diffracting the reference beam with the interference pattern, the reproduction beam is detected by a photodetector; and the information is reproduced by processing a signal detected by the photodetector.

    摘要翻译: 在用于从记录在信号光束和参考光束重叠时产生的干涉图案的介质中再现使用全息术的信息的光学信息再现方法中,参考光束以具有预定范围的参考光束角辐射到介质,以再现 信息,通过用干涉图案衍射参考光束来生成再现光束,再现光束由光电检测器检测; 并且通过处理由光电检测器检测的信号来再现信息。

    Reproduction apparatus and reproduction method
    2.
    发明授权
    Reproduction apparatus and reproduction method 有权
    繁殖装置和再现方法

    公开(公告)号:US08335147B2

    公开(公告)日:2012-12-18

    申请号:US13086421

    申请日:2011-04-14

    IPC分类号: G11B7/00

    CPC分类号: G11B7/00772 G11B7/08564

    摘要: In case of reproducing a hologram recorded on an optical information recording medium, adjusting beam with the amplitude distribution and phase distribution at least partially the same as those of a signal beam upon recording is radiated to the optical information recording medium which records information. The diffracting beam diffracted by the hologram is detected by a photodetector. Based on the detected information, an incident angle of the reference beam to the optical information recording medium is appropriately controlled.

    摘要翻译: 在再现记录在光学信息记录介质上的全息图的情况下,在记录信息的光学信息记录介质中照射具有与记录时的信号光束的幅度分布和相位分布至少部分相同的调整光束。 由全息图衍射的衍射光束由光电检测器检测。 基于检测到的信息,适当地控制参考光束对光信息记录介质的入射角度。

    REPRODUCTION APPARATUS AND REPRODUCTION METHOD
    3.
    发明申请
    REPRODUCTION APPARATUS AND REPRODUCTION METHOD 有权
    复制装置和再现方法

    公开(公告)号:US20110261671A1

    公开(公告)日:2011-10-27

    申请号:US13086421

    申请日:2011-04-14

    IPC分类号: G11B7/135

    CPC分类号: G11B7/00772 G11B7/08564

    摘要: In case of reproducing a hologram recorded on an optical information recording medium, adjusting beam with the amplitude distribution and phase distribution at least partially the same as those of a signal beam upon recording is radiated to the optical information recording medium which records information. The diffracting beam diffracted by the hologram is detected by a photodetector. Based on the detected information, an incident angle of the reference beam to the optical information recording medium is appropriately controlled.

    摘要翻译: 在再现记录在光学信息记录介质上的全息图的情况下,在记录信息的光学信息记录介质中照射具有与记录时的信号光束的幅度分布和相位分布至少部分相同的调整光束。 由全息图衍射的衍射光束由光电检测器检测。 基于检测到的信息,适当地控制参考光束对光信息记录介质的入射角度。

    SEMA5B peptides and vaccines including the same
    4.
    发明授权
    SEMA5B peptides and vaccines including the same 有权
    SEMA5B肽和疫苗包括它们

    公开(公告)号:US09187556B2

    公开(公告)日:2015-11-17

    申请号:US14118693

    申请日:2012-06-07

    摘要: As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译: 如本文详细讨论的,衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞(CTL),因此适合用于癌症免疫治疗,尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式,其中一个,两个或若干个氨基酸被取代,缺失,插入或添加,只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽,多核苷酸,药物或组合物特别用于治疗和/或预防癌症和肿瘤,包括例如食管癌,NSCLC,RCC和SCLC。

    ECT2 peptides and vaccines including the same
    7.
    发明授权
    ECT2 peptides and vaccines including the same 有权
    ECT2肽和疫苗包括它们

    公开(公告)号:US08951975B2

    公开(公告)日:2015-02-10

    申请号:US13638272

    申请日:2011-03-30

    摘要: Isolated peptides derived from SEQ ID NO: 42 and fragments thereof that bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines, are described herein. The inventive peptides encompass both the afore-mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are nucleic acids encoding any of the aforementioned peptides as well as pharmaceutical agents, substances and/or compositions that include or incorporate any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical agents, substances and compositions of this invention find particular utility in the treatment of cancers and tumors, including, for example, bladder cancer, breast cancer, cervical cancer, cholangiocellular carcinoma, CML, colorectal cancer, esophageal cancer, NSCLC, lymphoma, pancreatic cancer, prostate cancer, renal carcinoma and SCLC.

    摘要翻译: 衍生自SEQ ID NO:42的分离的肽及其与HLA抗原结合并诱导细胞毒性T淋巴细胞(CTL)的片段,因此适用于癌症免疫治疗,特别是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式,其中一个,两个或几个氨基酸被取代,缺失,插入或添加,只要这些修饰版本保留所需的HLA结合和/或CTL诱导性 的原始序列。 还提供了编码任何前述肽的核酸以及包括或掺入任何前述肽或核酸的药物,物质和/或组合物。 本发明的肽,核酸,药物,物质和组合物在治疗癌症和肿瘤方面特别有用,包​​括例如膀胱癌,乳腺癌,子宫颈癌,胆管细胞癌,CML,结肠直肠癌,食管癌 ,NSCLC,淋巴瘤,胰腺癌,前列腺癌,肾癌和SCLC。

    Method of diagnosing esophageal cancer
    9.
    发明授权
    Method of diagnosing esophageal cancer 有权
    诊断食管癌的方法

    公开(公告)号:US08771963B2

    公开(公告)日:2014-07-08

    申请号:US13246639

    申请日:2011-09-27

    摘要: In order to identify the molecules involved in esophageal carcinogenesis and those to be useful for diagnostic markers as well as targets for new drugs and immunotherapy, a cDNA microarray representing 32,256 genes was constructed to analyze the expression profiles of 19 esophageal squamous-cell carcinomas (ESCCS) purified by laser-capture microdissection. A detailed genome-wide database for sets of genes that are significantly up- or down-regulated in esophageal cancer is disclosed herein. These genes find use in the development of therapeutic drugs or immunotherapy as well as tumor markers. Additionally, genes associated with lymph-node metastasis and post-surgery recurrence are disclosed herein. Among the candidate molecular target genes, ECT2, CDC45L and DKK1 are further characterized. Treatment of ESCC cells with small interfering RNAs (siRNAs) of ECT2 or CDC45L suppressed growth of the cancer cells. Thus, the data herein provide valuable information for identifying diagnostic systems and therapeutic target molecules for esophageal cancer.

    摘要翻译: 为了鉴定涉及食管癌发生的分子以及可用于诊断标志物以及新药和免疫治疗靶标的分子,构建了代表32,256个基因的cDNA微阵列,分析19例食管鳞状细胞癌(ESCCS)的表达谱 )通过激光捕获显微切割纯化。 本文公开了在食管癌中显着上调或下调的基因组的详细全基因组数据库。 这些基因可用于治疗药物或免疫治疗以及肿瘤标志物的开发。 此外,本文公开了与淋巴结转移和手术后复发相关的基因。 在候选分子靶基因中,进一步表征ECT2,CDC45L和DKK1。 用ECT2或CDC45L的小干扰RNA(siRNA)处理ESCC细胞抑制癌细胞的生长。 因此,本文的数据提供了用于鉴定诊断系统和用于食管癌的治疗靶分子的有价值的信息。

    SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME
    10.
    发明申请
    SEMA5B PEPTIDES AND VACCINES INCLUDING THE SAME 有权
    SEMA5B肽和疫苗,包括它们

    公开(公告)号:US20140178409A1

    公开(公告)日:2014-06-26

    申请号:US14118693

    申请日:2012-06-07

    IPC分类号: C07K16/18

    摘要: As discussed in detail herein, isolated epitope peptides derived from SEMA5B bind to an HLA antigen and induce cytotoxic T lymphocytes (CTL) and thus are suitable for use in the context of cancer immunotherapy, more particularly cancer vaccines. The inventive peptides encompass both the above mentioned amino acid sequences and modified versions thereof, in which one, two, or several amino acids are substituted, deleted, inserted or added, provided such modified versions retain the requisite HLA binding and/or CTL inducibility of the original sequences. Further provided are polynucleotides encoding any of the aforementioned peptides as well pharmaceutical agents or compositions that include any of the aforementioned peptides or polynucleotides. The peptides, polynucleotides, pharmaceutical agents or compositions of this invention find particular utility in the treatment and/or prevention of cancers and tumors, including, for example, esophageal cancer, NSCLC, RCC and SCLC.

    摘要翻译: 如本文详细讨论的,衍生自SEMA5B的分离的表位肽结合HLA抗原并诱导细胞毒性T淋巴细胞(CTL),因此适合用于癌症免疫治疗,尤其是癌症疫苗的上下文中。 本发明的肽包括上述氨基酸序列及其修饰形式,其中一个,两个或若干个氨基酸被取代,缺失,插入或添加,只要这些修饰版本保持必需的HLA结合和/或CTL诱导性 原始序列。 还提供了编码任何上述肽的多核苷酸以及包括任何上述肽或多核苷酸的药物试剂或组合物。 本发明的肽,多核苷酸,药物或组合物特别用于治疗和/或预防癌症和肿瘤,包括例如食管癌,NSCLC,RCC和SCLC。